<DOC>
	<DOCNO>NCT01864187</DOCNO>
	<brief_summary>Dexmedetomidine hydrochloride , relatively new drug Chinais , highly selective , potent a2-adrenoceptor agonist significant analgesic , sedative anxiolytic effect . The morbid obesity Chinese population rapidly increase . But pharmacokinetics drug people still unknown.This research design study pharmacokinetics dexmedetomidine Chinese morbidly obese population .</brief_summary>
	<brief_title>Pharmacokinetics Dexmedetomidine Morbid Obesity</brief_title>
	<detailed_description>For obese sensitive disease hypertension , ischaemic heart disease diabetes , change state may affect pharmacokinetics dexmedetomidine . Besides , clearance dexmedetomidine parallel liver function excrete kidney , difference obese may expect . About 10 obese patient 10 match healthy volunteer normal weight would choose receive normal dosage dexmedetomidine . And venous sample collect different time point . Next investigator get plasma concentration dexmedetomidine use HPLC-MS. And plasma concentration could analyze .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Weight:28≦BMI≦45 18.5≦BMI≦24 2 . Written informed consent patient relatives participate patient . 1 . A previous history intolerance study drug relate compound additive . 2 . Existing significant haematological , endocrine , metabolic gastrointestinal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Obesity</keyword>
</DOC>